Komori
Occurring Fact4592SanBio Company LimitedPharmaceuticals

Notice Regarding the Recognition of Non-Operating Income, Non-Operating Expenses and Adjustments to Income Taxes

In the second quarter of the fiscal year ending January 2027, the Company recorded non-operating income including ¥185 million in foreign exchange gains and ¥22 million in interest income, while also recording ¥11 million in financing costs, ¥16 million in interest on bonds and ¥58 million in adjustments to income taxes.

Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
185
¥ million (foreign exchange gain)
Wording
Definitive
How definitive the wording is.

Recognition of Non-Operating Income, Non-Operating Expenses and Adjustments to Income Taxes

Subject Entity

Transactions relating to SanBio Company Limited and its consolidated subsidiaries

Target Locations / Products

Time deposits, foreign-currency loans to consolidated subsidiaries and related receivables, the commitment line agreement, and Series 1 Unsecured Convertible Bonds with Stock Acquisition Rights

Occurrence1 February 2026 to 31 July 2026 (the recognition period for the second quarter of the fiscal year ending January 2027; not a specific date)
This disclosure09/14/2026
Cause

Fluctuations in foreign exchange rates, interest income from the management of time deposits and foreign-currency loans, fees under the commitment line agreement and other items, interest on bonds issued, and the recognition of deferred tax liabilities relating to foreign-currency loans and related receivables

Amount of Impact on Business Performance

Non-operating income (foreign exchange gains): ¥185 million; non-operating income (interest income): ¥22 million; non-operating expenses (financing costs): ¥11 million; non-operating expenses (interest on bonds): ¥16 million; adjustments to income taxes: ¥58 million. The foreign currency translation adjustment of negative ¥142 million is treated as an adjustment item in other comprehensive income.

Accounting period in which recognized

Second quarter of the fiscal year ending January 2027 (1 February 2026 to 31 July 2026). Financing costs cover the cumulative second-quarter period. For interest on bonds, the main text states "1 February 2025 to 31 July 2026."

Impact on Earnings Forecast

The document states that readers should refer to the "Second-Quarter Financial Results Summary for the Fiscal Year Ending January 2027 [Japanese GAAP] (Consolidated)" published today, but it contains no information on whether the earnings forecast was revised or on the revised figures.

Event that occurred
ItemDetails
Event nameRecognition of Non-Operating Income, Non-Operating Expenses and Adjustments to Income Taxes
Date of occurrence1 February 2026 to 31 July 2026 (the recognition period for the second quarter of the fiscal year ending January 2027; not a specific date)
Subject EntityTransactions relating to SanBio Company Limited and its consolidated subsidiaries
Target Locations / ProductsTime deposits, foreign-currency loans to consolidated subsidiaries and related receivables, the commitment line agreement, and Series 1 Unsecured Convertible Bonds with Stock Acquisition Rights
CauseFluctuations in foreign exchange rates, interest income from the management of time deposits and foreign-currency loans, fees under the commitment line agreement and other items, interest on bonds issued, and the recognition of deferred tax liabilities relating to foreign-currency loans and related receivables
Amount of Impact on Business PerformanceNon-operating income (foreign exchange gains): ¥185 million; non-operating income (interest income): ¥22 million; non-operating expenses (financing costs): ¥11 million; non-operating expenses (interest on bonds): ¥16 million; adjustments to income taxes: ¥58 million. The foreign currency translation adjustment of negative ¥142 million is treated as an adjustment item in other comprehensive income.
Accounting period in which recognizedSecond quarter of the fiscal year ending January 2027 (1 February 2026 to 31 July 2026). Financing costs cover the cumulative second-quarter period. For interest on bonds, the main text states "1 February 2025 to 31 July 2026."
Impact on Earnings ForecastThe document states that readers should refer to the "Second-Quarter Financial Results Summary for the Fiscal Year Ending January 2027 [Japanese GAAP] (Consolidated)" published today, but it contains no information on whether the earnings forecast was revised or on the revised figures.
Items this document does not state (17)
Date recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

These resulted from fluctuations in foreign exchange rates, interest income from the management of time deposits and foreign-currency loans, fees under the commitment line agreement and other items, interest on bonds issued, and the recognition of deferred tax liabilities relating to foreign-currency loans and other items.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recognition of Non-Operating Income, Non-Operating Expenses and Adjustments to Income Taxes | SanBio Company Limited (4592) timely disclosure | Komori